NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Is Expedia Group (EXPE) Now Attractive After Recent Share Price Pullback?

If you are wondering whether Expedia Group's recent share price still offers value, it helps to line up what you are paying today against what the business could reasonably justify over time. The stock last closed at US$271.56, with a 7 day return of a 6.6% decline, a 30 day return of a 6.1% decline, a year to date return of a 4.0% decline, and longer term returns of 57.6% over 1 year, 135.1% over 3 years, and 122.2% over 5 years. Recent news around Expedia Group has focused on its role as a...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Old National Bancorp (ONB) Earnings Growth Reinforces Bullish Narratives Despite Lower Net Margin

Old National Bancorp (ONB) just closed out FY 2025 with fourth quarter revenue of US$648.0 million and basic EPS of US$0.55, alongside trailing twelve month revenue of about US$2.3 billion and EPS of US$1.80. The bank has seen revenue move from US$458.4 million in Q4 2024 to US$648.0 million in Q4 2025, with basic EPS shifting from US$0.47 to US$0.55 over the same period, which sets the backdrop for how investors weigh its earnings profile. With a trailing net profit margin of 28.4% and a...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Does Exelixis’ (EXEL) 2026 Zanzalintinib Rollout and Buybacks Shift Its Oncology Growth Narrative?

Exelixis recently completed two share repurchase programs totaling approximately US$660 million and reported preliminary 2025 results alongside 2026 revenue guidance centered on its oncology portfolio. A key element of this update is the emphasis on zanzalintinib’s expected first commercial availability for multiple cancer indications in 2026, supported by a new collaboration with Natera. We’ll now examine how Exelixis’ 2026 revenue guidance, anchored by the anticipated rollout of...
NasdaqGS:HQY
NasdaqGS:HQYHealthcare

Did New FY 2027 Revenue Guidance and JPM Spotlight Just Shift HealthEquity's (HQY) Investment Narrative?

In January 2026, HealthEquity, Inc. issued earnings guidance for the fiscal year ending January 31, 2027, projecting revenues between US$1.38 billion and US$1.41 billion, and presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. This combination of a clearer revenue outlook and high-profile conference exposure provided investors with fresh information about management’s expectations and positioning within the healthcare benefits space. We’ll now examine how...
NYSE:HE
NYSE:HEElectric Utilities

Is Hawaiian Electric (HE) Pricing In Too Much Optimism After Its Recent Share Price Rebound

If you are wondering whether Hawaiian Electric Industries is attractively priced after a turbulent few years, you are not alone. The stock last closed at US$14.72, with returns of 4.9% over 7 days, 25.3% over 30 days, 16.5% year to date, but a 60.5% gain over 1 year sits against a 63.0% decline over 3 years and a 51.5% decline over 5 years. Recent market attention has focused on how investors are reassessing Hawaiian Electric Industries following past events and ongoing regulatory and...
NYSE:OXY
NYSE:OXYOil and Gas

A Look At Occidental Petroleum (OXY) Valuation As Dividend Hike Bets Grow After OxyChem Sale

Occidental Petroleum (OXY) is back in focus as investors look ahead to its February 19 Q4 earnings release, where many expect another dividend increase following the recent US$9.7b OxyChem sale. See our latest analysis for Occidental Petroleum. The share price has picked up into earnings, with a 1 day share price return of 3.01% and a 30 day share price return of 8.05%. However, the 1 year total shareholder return of 11.42% and 3 year total shareholder return of 29.13% are still weak compared...
NYSE:F
NYSE:FAuto

Is Ford Motor (F) Shares Attractive After EV And Software Expansion Headlines?

If you are wondering whether Ford Motor's share price still offers value at around US$13.77, you are not alone. This article is set up to help you frame that question clearly. Over the last week the stock showed a 0.5% decline, while the 1 year return of 47.5% and 5 year return of 68.2% point to a very different experience for longer term holders. Recent headlines have focused on Ford Motor's ongoing push in electric vehicles and software centric features, as well as its role in the broader...
NYSE:SMR
NYSE:SMRElectrical

Assessing NuScale Power (SMR) Valuation After Oak Ridge Study Validates SMR Industrial Use Potential

NuScale Power (SMR) is back in focus after a new Oak Ridge National Laboratory study found its 77 MWe small modular reactors can reliably and cost effectively power large chemical plants and supply process steam. See our latest analysis for NuScale Power. The Oak Ridge findings arrive after a sharp share price pullback in recent months, with NuScale’s 30 day share price return of 20.21% and year to date share price return of 21.09% contrasting with a 1 year total shareholder return of 22.76%...
NasdaqGS:WMT
NasdaqGS:WMTConsumer Retailing

Is Walmart’s Nasdaq-100 Debut and AI Retail Push Altering The Investment Case For Walmart (WMT)?

Walmart has joined the Nasdaq-100 Index while advancing its retail-tech push, including launching a Premium Musical Instrument Shop on Walmart Marketplace and deepening AI-powered shopping collaborations with Google’s Gemini platform. These moves, alongside the elevation of e-commerce veteran David Guggina to CEO of Walmart U.S., highlight how Walmart is repositioning itself as much as a technology and platform company as a traditional retailer. We’ll now examine how Walmart’s Nasdaq-100...
NYSE:OTIS
NYSE:OTISMachinery

Should Otis’s Gen3 IoT Elevator Expansion in EMEA Reframe Its Smart-Building Narrative for (OTIS) Investors?

On January 21, 2026, Otis expanded its Gen3 elevator family across Europe, the Middle East and Africa, embedding Otis ONE IoT, energy-saving ReGen drives and advanced safety features into eight connected products for low- to mid-rise buildings. This rollout highlights how elevator systems are becoming smarter infrastructure, combining predictive maintenance, energy efficiency and highly customizable passenger experiences in a single platform. Next, we’ll examine how this Gen3 IoT-enabled...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead Sciences (GILD) Valuation Check After Trodelvy Keytruda Phase 3 Success And Regulatory Progress

Gilead Sciences (GILD) is back in focus after detailed Phase 3 ASCENT-04/KEYNOTE-D19 results in The New England Journal of Medicine showed that Trodelvy plus Keytruda cut the risk of progression or death by 35% compared with standard care. See our latest analysis for Gilead Sciences. The latest Trodelvy data and other pipeline updates appear to be feeding into a constructive trend, with a 1-day share price return of 4.0% and a 90-day share price return of 6.9%, while the 1-year total...
NYSE:FTI
NYSE:FTIEnergy Services

The Bull Case For TechnipFMC (FTI) Could Change Following A US$2 Billion Buyback And Surging Volume

On 19 January 2026, TechnipFMC plc saw unusually high after-hours trading volume of 33,483,267 shares on EURONEXT, following a board-authorized share repurchase program of about US$2.00 billion. This combination of intense trading activity and a large buyback authorization highlights how capital return decisions can rapidly concentrate market attention on TechnipFMC’s equity. Next, we’ll explore how TechnipFMC’s sizeable share repurchase plan shapes its investment narrative in light of...
NYSE:ALG
NYSE:ALGMachinery

Assessing Alamo Group (ALG) Valuation After Recent Share Price Momentum

Why Alamo Group stock is on investors’ radar Alamo Group (ALG) has moved onto investor watchlists after its recent share performance, with the stock around $191.95 and showing positive total returns over the past month and past 3 months. See our latest analysis for Alamo Group. That recent 11.38% 1 month share price return, alongside a 12.63% share price return year to date and a 5.15% total shareholder return over the past year, points to momentum that has been building rather than...
NYSE:HPQ
NYSE:HPQTech

Do Wall Street’s Split Views On HP’s (HPQ) PC And Printing Headwinds Reveal A Deeper Risk?

Earlier in January, Barclays and Goldman Sachs downgraded HP Inc., flagging long-term pressures across its core PC and printing businesses alongside margin concerns. The downgrades highlight a tension between cautious analyst views on structural headwinds and broader Wall Street opinions that still view HP’s prospects more positively. Next, we’ll examine how these concerns about secular PC and printing challenges could shape HP’s investment narrative for investors. AI is about to change...
NYSE:CVS
NYSE:CVSHealthcare

CVS Health Backs Yeztugo PrEP Coverage And Broadens HIV Prevention Role

CVS Health (NYSE:CVS) is moving to cover Yeztugo, the first long acting injectable HIV prevention drug, following its recent FDA approval. Yeztugo is designed as a twice yearly PrEP injection, offering an alternative to daily oral HIV prevention medications. This coverage decision places CVS Health alongside other major pharmacy benefit managers that are adding Yeztugo to their formularies. For CVS Health, which runs one of the largest pharmacy benefit managers alongside its retail...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Is Costco (COST) Using Dividends And Gas Rewards To Redefine Its Membership Value Strategy?

Costco Wholesale’s board recently declared a quarterly cash dividend of US$1.30 per share, payable on February 13, 2026, to shareholders of record as of January 30, 2026. Alongside this dividend, Costco is reinforcing its membership-centric model through moves like higher gas rewards, expanded bakery offerings, and technology upgrades that aim to deepen loyalty and support its warehouse expansion. We’ll now examine how Costco’s focus on strengthening membership value, especially via richer...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

A Look At Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Collaboration

Why the latest FDA filing and GSK collaboration matter for Summit Therapeutics Summit Therapeutics (SMMT) has drawn fresh attention after filing a Biologics License Application with the FDA for ivonescimab in EGFR-mutated non small cell lung cancer, alongside a new clinical collaboration with GSK across multiple solid tumors. See our latest analysis for Summit Therapeutics. The recent FDA Biologics License Application and GSK trial collaboration arrive after a mixed year for the stock, with a...
NasdaqGS:JKHY
NasdaqGS:JKHYDiversified Financial

Jack Henry Expands Instant Payments And Digital Assets As Valuation Stays Stretched

Jack Henry & Associates (NasdaqGS:JKHY) has launched Rapid Transfers, a cloud-native service for me-to-me payments, expanding its fintech capabilities for banks and credit unions. Coinbax has joined Jack Henry's Fintech Integration Network, adding support for compliant stablecoin transactions and programmable escrow for institutional clients. For investors watching how core banking providers respond to rising expectations for speed and convenience, these moves put a spotlight on where Jack...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian Automotive (RIVN) Valuation Check As R2 SUV And Software Expansion Attract New Attention

Rivian Automotive (RIVN) has attracted fresh attention as it prepares the R2 mass market SUV, a lower priced model aimed at reigniting deliveries while the company ramps plants, software and subscription based autonomous driving services. See our latest analysis for Rivian Automotive. At a share price of US$16.47, Rivian’s 30 day share price return of a 24.28% decline contrasts with a 25.82% gain over 90 days and a 29.79% total shareholder return over one year. This suggests momentum has...
NYSE:O
NYSE:ORetail REITs

Is It Too Late To Consider Realty Income (O) After Its Recent Share Price Rise?

Wondering whether Realty Income at around its recent US$61.79 close still offers value, or if most of the easy upside is already priced in? This article is built to help you frame that question clearly. The stock has returned 2.5% over the last 7 days, 9.0% over 30 days, 7.8% year to date and 21.1% over the last year, with total returns of 8.3% over 3 years and 36.0% over 5 years. This naturally raises questions about how its current price lines up against its fundamentals. Recent coverage...
NasdaqCM:BULL
NasdaqCM:BULLCapital Markets

Does Webull (BULL) Embedding Level2’s No‑Code Tools Hint At A Deeper Platform Strategy Shift?

On January 13, 2026, Level2 announced a partnership to embed its no-code automated trading tools directly into Webull’s US trading platform, giving retail users visual strategy building, real-time backtesting, and seamless execution in one place. This move targets a clear gap for institutional-style automation among retail traders, potentially reshaping how Webull’s community designs, tests, and shares trading approaches. Next, we’ll examine how Webull’s new no-code automation capabilities...
NYSE:LHX
NYSE:LHXAerospace & Defense

L3Harris Pentagon Investment And Missile Spin Off Reshape Growth Profile

L3Harris Technologies (NYSE:LHX) is set to receive a US$1b investment from the U.S. Department of Defense into its solid rocket motors business. The company plans a public spin off of its Missile Solutions division, targeted for later in 2026. The structure is intended to allow direct U.S. government ownership in the spun off missile business while L3Harris remains the majority shareholder. L3Harris, a major defense and aerospace contractor, is closely tied to U.S. national security...
NYSE:CW
NYSE:CWAerospace & Defense

Is Curtiss-Wright’s Safety-Certifiable Multicore Push Reshaping Its Aerospace and Defense Narrative (CW)?

Curtiss-Wright and Green Hills Software recently announced a new COTS platform that combines Curtiss-Wright’s SOSA-aligned V3-1222 3U VPX processing module with Green Hills’ FACE-certified INTEGRITY-178 tuMP real-time operating system to deliver safety-certifiable multicore computing for aerospace, defense, and industrial applications. An interesting aspect of this announcement is how the platform targets the highest functional safety and security standards, enabling certifiable multicore...
NasdaqGS:FITB
NasdaqGS:FITBBanks

Fifth Third Bancorp (FITB) Net Interest Margin Stability Reinforces Bullish Narratives

Fifth Third Bancorp (FITB) has rounded out FY 2025 with fourth quarter revenue of US$2.2 billion and basic EPS of US$1.05, while trailing twelve month EPS sits at US$3.56 on revenue of US$8.4 billion and net income of US$2.4 billion. The company has seen revenue move from US$2.0 billion and EPS of US$0.86 in Q4 2024 to US$2.2 billion and EPS of US$1.05 in Q4 2025. On a trailing basis, revenue has shifted from US$8.0 billion and EPS of US$3.16 to US$8.4 billion and EPS of US$3.56, which may...